🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

58 results for “Daiichi Sankyo” Clear

  1. CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB

    Daiichi Sankyo

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. CS-3150

    Daiichi Sankyo

    Hypertension

    phase 3 small molecule completed

    1 trial

  4. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a

    Daiichi Sankyo

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  5. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ribozar 1 g Pulver zur Herstellung einer Infusionslösung, Datopotamab deruxtecan, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  6. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  7. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  8. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  9. Datopotamab deruxtecan, DOCETAXEL

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  11. Edoxaban

    Daiichi Sankyo

    Cardiac Disease

    phase 3 small molecule completed

    1 trial

  12. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  13. Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL

    Daiichi Sankyo

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Datopotamab deruxtecan, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  15. PACLITAXEL, Cyramza 10 mg/ml concentrate for solution for infusion, DS-8201a, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion

    Daiichi Sankyo

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. PACLITAXEL, Raludotatug Deruxtecan, TOPOTECAN, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Daiichi Sankyo

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  17. TOPOTECAN, TOPOTECAN, Ifinatamab deruxtecan

    Daiichi Sankyo

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  18. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  20. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  21. VEGZELMA 25 mg/mL concentrate for solution for infusion, DS-8201a

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  22. edoxaban tosylate(DU-176b)

    Daiichi Sankyo

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  23. 10mg DS-8500a tablet

    Daiichi Sankyo

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. CARBOPLATIN, ATEZOLIZUMAB, ETOPOSIDE, Ifinatamab deruxtecan

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources